UBS analyst Laura Sutcliffe downgraded GlaxoSmithKline to Neutral and lowered her price target for the shares to 1,650p from 1,700p. Concerns around the company’s HIV franchise are likely to keep a lid on the shares, Sutcliffe tells investors in a research note. Further, she believes consensus estimates for 2019 are “slightly too high.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.